TheraRadar
← Back
Data updated: Sep 20, 2026

ACELLA

Generics

ACELLA is a generic drug manufacturer focused on Cardiovascular, Infectious Disease.

1974
Since
11
Drugs
-
Trials
0
New Drugs (2yr)

ACELLA's Key Drugs

ACELLA's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).

No active drugs

ACELLA's Recent FDA Approvals

New NDA/BLA approvals for ACELLA over the last two years — novel drugs only, excluding generics and label supplements.

No recent approvals

ACELLA's Therapeutic Areas

ACELLA's approved drugs and pipeline span 2 therapeutic areas, led by Cardiovascular and Infectious Disease. Weighted by commercial stage — approved drugs count most, then late-stage trials.

Cardiovascular 50%
1 drugs
Infectious Disease 50%
1 drugs

ACELLA's Top Competitors

ACELLA's closest competitors by therapeutic-area and drug-target overlap include Merck, Baxter, and Sanofi. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.

ACELLA Pipeline Snapshot

Active clinical trials for ACELLA across all therapeutic areas, from ClinicalTrials.gov.

No active pipeline data available

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • Top drug revenue breakdown
  • Drug-level revenue analysis

Trial Catalysts

  • Cardiovascular pipeline focus
  • Phase 3 readout tracking

Patent Risk

  • Patent expiration timeline
  • Revenue at risk analysis

Compare Companies

  • Side-by-side pipeline analysis
  • Revenue & market share comparison
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling